Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support.
Meryem EzzitounyEsther Roselló-LletíManuel PortolésIgnacio Sánchez-LázaroMiguel Ángel Arnau-VivesEstefanía TarazónCarolina Gil-CayuelaSilvia Lozano-EdoRaquel López-VilellaLuis Almenar-BonetLuis Martínez DolzPublished in: Journal of personalized medicine (2021)
In this cohort, patients with advanced HF and a need for MCS have shown significantly lower levels of SERCA2a as compared to stable patients without a need for MCS prior to heart transplantation. This is a small study with preliminary findings, and larger-powered dedicated studies are required to confirm and validate these results.